The Pennant Group (PNTG) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
15 Jan, 2026Executive summary
Q3 2024 revenue reached $180.7 million, up 28.9% year-over-year, driven by strong growth in home health, hospice, and senior living segments.
Net income for Q3 2024 was $6.2 million, a 41.6% increase from the prior year; GAAP diluted EPS was $0.20, and adjusted EPS was $0.26.
Adjusted EBITDA for Q3 2024 was $15.7 million, up 39.2% year-over-year; adjusted net income was $8.2 million, up 36.8%.
Growth was supported by acquisitions of multiple home health, hospice agencies, and senior living communities during the year.
Recent equity offering and expanded revolving credit facility post-quarter enhanced financial flexibility and resulted in zero debt.
Financial highlights
Q3 2024 consolidated revenue: $180.7 million (+28.9% YoY); adjusted EBITDA: $15.7 million (+39.2% YoY); adjusted EBITDAR: $26.0 million (+25.9% YoY).
Adjusted EPS for Q3 2024 was $0.26; GAAP diluted EPS was $0.20.
Net income for Q3 2024 was $6.2 million; adjusted net income was $8.2 million.
Cash at quarter end: $4.5 million; net cash from operations (nine months): $18.7 million.
Gross margin for Q3 2024 was 20.0%; operating margin was 6.0%.
Outlook and guidance
2024 annual adjusted revenue guidance raised to $665.3–$706.5 million; adjusted EBITDA guidance increased to $51.9–$55.2 million; adjusted EPS guidance now $0.90–$0.96.
Guidance reflects strong operations, hospice rate adjustments, lower interest expense, and JV contributions.
Guidance excludes unannounced acquisitions, announced purchase of Signature's Oregon assets, start-ups, share-based compensation, and one-time items.
Management expects margin fluctuation due to acquisitions and integration of new operations.
Anticipates ongoing competitive and inflationary pressures in senior living, impacting occupancy and rate growth.
Latest events from The Pennant Group
- Q2 revenue up 35.8% to $298M, with guidance raised on strong growth and acquisitions.PNTG
Q2 2026 - Acquisitions, quality focus, and leadership development fueled growth and margin gains in 2025.PNTG
Stephens Annual Investment Conference - Moratorium impact limited; strong growth in Home Health and Senior Living continues.PNTG
RBC Capital Markets Global Healthcare Conference 2026 - Q1 2026 revenue rose 36% to $285.4M, with strong segment growth and margin expansion.PNTG
Q1 2026 - Board recommends approval of all proposals, emphasizing governance and pay-for-performance.PNTG
Proxy filing - Major acquisitions fuel growth, with integration and margin expansion as top priorities.PNTG
Oppenheimer 36th Annual Healthcare MedTech & Services Conference - Record 2025 revenue and EPS growth, with 2026 guidance projecting further double-digit gains.PNTG
Q4 2025 - Expanding in the Southeast, leveraging local leadership, and preparing for regulatory changes.PNTG
Jefferies 2025 Healthcare Services Conference - Q2 revenue up 27.6%, net income doubled, and guidance raised on strong segment growth.PNTG
Q2 2024